The U.S. Food and Drug Administration
approved Moderna’s mRNA-1345 vaccine is said to protect adults aged 60 years and older from lower respiratory tract disease caused by respiratory syncytial virus infection.
Distributor
Breakthrough Therapy Designation The approval of the drug, marketed as mResvia, marks the second Moderna drug to be approved by the FDA and, more importantly, the first mRNA vaccine approved to treat a disease other than COVID-19.
“Your application was not consulted with the Vaccines and Related Biological Products Advisory Committee.”
This would be a big step, but regulators seemed eager to jump ahead to another level of scrutiny.
The FDA
I got it. “After reviewing the information submitted in the application, we decided not to refer the application to the Vaccines and Related Biological Products Advisory Committee,” Friday’s approval letter said. [biologics license application]”No concerns or controversial issues regarding clinical trial design or trial results were raised that would benefit from discussion by the advisory committee.”
Advisory Committee work Its purpose is to review and evaluate data on the “safety, efficacy and appropriate use of vaccines and related biological products” and then provide independent expert advice to authorities.
according to The drugmaker said the approval was based on “positive data from the Phase 3 clinical trial ConquerRSV, an international study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.”
About 20,000 of the study participants were US residents. Eleven other studies are ongoing Examine the impact of new drugs on other demographics.
In a February 29 announcement, the company said:
overview Trial data showed the vaccine “maintained efficacy through a mean follow-up period of 8.6 months” and “was shown to prevent severe RSV infection, based on an analysis of respiratory distress and physician-reported RSV infections.”[lower respiratory tract disease]”
The vaccine is said to be 83.7% effective. Reuters I got it.But the label says the vaccine is only 79% effective in preventing at least two of RSV symptoms, such as fever and cough.
While the summary asserts that the vaccine is relatively effective and safe, it nevertheless highlights several “systemic reactions” reported within seven days of receiving the vaccine, including headache, fatigue, muscle and joint pain and chills, in addition to the usual injection site pain.
Funded by Moderna
study A paper published in the New England Journal of Medicine similarly claimed that a single dose of the vaccine “did not raise any obvious safety concerns.”
Similarly, despite being announced as a safe vaccine, the Moderna COVID-19 vaccine
Linked In various studies, FDA-Funded ResearchMen aged 18 to 25 years are especially at risk of myocarditis and pericarditis.
In addition to cardiac inflammation, the Global COVID Vaccine Safety Project, an effort of the Global Vaccine Data Network supported by both the CDC and the Department of Health and Human Services,
Revealed A February study in the respected journal Vaccine found that “Bell’s palsy is [observed to expected] Proportion after first dose [Pfizer’s] BNT162b2 and [Moderna’s] “mRNA-1273”
The study also noted that “the OE ratio of febrile convulsions was also increased after the first and second doses of mRNA-1273, and the OE ratio of generalized convulsions was also increased after the first dose of mRNA-1273 and the fourth dose of BNT162b2.”
The Blaze News previously reported that the University of Auckland, which hosts the Global Vaccine Data Network, noted there were safety indications of “acute disseminated encephalomyelitis (inflammation and swelling of the brain and spinal cord) following vaccination with viral vector and mRNA vaccines.”
Despite concerns about the only other approved vaccine, Moderna seems confident in its product and has apparently secured the FDA’s trust. The company’s next stop is the Centers for Disease Control and Prevention, where the agency’s Advisory Committee on Immunization Practices is scheduled to review the vaccine at a meeting June 26-27.
Analysts predict Moderna will sell about $340 million of its RSV vaccine this year, which could reach $830.5 million by 2025. report Reuters.
Like Blaze News? Bypass the censorship and sign up for our newsletter to get stories like this one directly to your inbox. Register here!
